Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Cellular and Molecular Tumorbiology / Maria Sibilia
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
      • Maria Sibilia
        • Research Projects
        • Group Members
      • Robert Eferl
      • Andrea Gsur
      • Erich Heidenreich
      • Dietmar Herndler-Brandstetter
      • Joanna Loizou
      • Ferdinand Steinböck
    • Applied and Experimental Oncology
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Maria Sibilia, Univ.-Prof. Mag. Dr.
Head of Center
Coordinator of Research Focus "Cellular and Molecular Tumorbiology"
Group Leader

E-Mail: maria.sibilia [at] meduniwien [dot] ac [dot] at
Phone.:  +43 (0)1 40160 - 57501 or 57502
Fax: +43 (0)1 40160 - 957502

Research Focus

Tumors are increasingly being recognized as organs consisting of cancer cells and a variety of cells composing the ”tumor microenvironment” which include immune cells, vascular cells and fibroblasts. These stromal cells significantly contribute to malignant progression. Using the mouse as a model system we aim to understand the role of Epidermal Growth Factor Receptor (EGFR) signaling in cancer cells, in tumor stromal cells and their complex interaction. The ultimate goal is to translate this knowledge to human patients to develop rational and effective therapies for the treatment of human cancer.
 

Fundings

Group Members

Videos

FWF Video

Immune research for improved cancer therapies from Wissenschaftsfonds FWF on Vimeo.

Selected Publications:

The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity.
Novoszel P, Drobits B, Holcmann M, Fernandes CS, Tschismarov R, Derdak S, Decker T, Wagner EF, Sibilia M.
Cell Death Differ. 2021 Aug;28(8):2404-2420. doi: 10.1038/s41418-021-00765-4. Epub 2021 Mar 23.

Psoriatic skin inflammation is promoted by c-Jun/AP-1-dependent CCL2 and IL-23 expression in dendritic cells.
Novoszel P, Holcmann M, Stulnig G, De Sa Fernandes C, Zyulina V, Borek I, Linder M, Bogusch A, Drobits B, Bauer T, Tam-Amersdorfer C, Brunner PM, Stary G, Bakiri L, Wagner EF, Strobl H, Sibilia M.
EMBO Mol Med. 2021 Apr 9;13(4):e12409. doi: 10.15252/emmm.202012409. Epub 2021 Mar 16.

Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy.
Jörg Klufa, Thomas Bauer, Buck Hanson, Craig Herbold, Philipp Starkl, Beate Lichtenberger, Dagmar Srutkova, Daniel Schulz, Igor Vujic, Thomas Mohr, Klemens Rappersberger, Bernd Bodenmiller, Hana Kozakova, Sylvia Knapp, Alexander Loy, Maria Sibilia; Sci Transl Med. 2019 Dec 11;11(522):eaax2693. doi: 10.1126/scitranslmed.aax2693.

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.
Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP, Kenner L, Wrba F, Prager GW, Rose-John S, Eferl R, Liguori G, Botti G, Martinelli E, Greten FR, Ciardiello F, Sibilia M.; Gastroenterology. 2017 Jul;153(1):178-190.e10. doi: 10.1053/j.gastro.2017.03.053. Epub 2017 Apr 9.

EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling.
Linder M, Glitzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, Dumanic M, Novoszel P, Mohr T, Langer O, Wanek T, Mitterhauser M, Wagner EF, Sibilia M.; EMBO Mol Med. 2018 Nov;10(11). pii: e9408. doi: 10.15252/emmm.201809408.

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.
Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M, Sieghart W, Trauner M, Wang H, Sibilia M.; Nat Cell Biol. 2014 Oct; 16(10):972-81, 1-7.

Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, Schrumpf H, Boelke E, Ansari P, Mackenzie C, Wollenberg A, Kislat A, Fischer JW, Röck K, Harder J, Schröder JM, Homey B, Sibilia M.; Sci Transl Med. 2013 Aug 21; 5(199):199

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M.; J Clin Invest. 2012 Feb 1; 122(2):575-85.   

Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development.
Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M.; Cell. 2010 Jan 22; 140(2):268-79.
 

All Publications:

PubMedDatabase

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact